Characteristics | RA Cohort | Non-RA Cohort | ||||||
---|---|---|---|---|---|---|---|---|
Overall, n = 813 | 1980–1989, n = 202 | 1990–1999, n = 296 | 2000–2007, n = 315 | Overall, n = 813 | 1980–1989, n = 202 | 1990–1999, n = 296 | 2000–2007, n = 315 | |
Age, yrs, mean (± SD) | 55.9 (15.7) | 57.4 (15.8) | 56.1 (15.8) | 54.6 (15.4) | 55.9 (15.7) | 57.4 (15.8) | 56.2 (15.8) | 54.6 (15.4) |
Female | 556 (68) | 138 (68) | 195 (66) | 223 (71) | 556 (68) | 138 (68) | 195 (66) | 223 (71) |
Cigarette smoking at RA incidence | ||||||||
Never smoked | 364 (45) | 79 (39) | 123 (42) | 162 (51) | 435 (54) | 101 (50) | 165 (56) | 169 (54) |
Current smoking | 178 (22) | 68 (34) | 59 (20) | 51 (16) | 144 (18) | 52 (26) | 39 (13) | 52 (17) |
Former smoking | 271 (33) | 55 (27) | 114 (38) | 102 (32) | 234 (29) | 49 (24) | 92 (31) | 93 (30) |
Obesity at RA incidence, BMI ≥ 30 kg/m2 | 244 (30) | 34 (17) | 83 (28) | 127 (40) | 229 (28) | 30 (14) | 70 (24) | 129 (41) |
CV risk factors at incidence/index | ||||||||
Hypertension | 313 (38) | 78 (39) | 103 (35) | 132 (42) | 278 (34) | 66 (33) | 87 (29) | 125 (40) |
Antihypertensive medication use | 226 (28) | 51 (25) | 73 (25) | 102 (32) | 210 (26) | 52 (26) | 60 (20) | 98 (31) |
Diabetes mellitus | 80 (10) | 22 (11) | 23 (8) | 35 (11) | 68 (8) | 15 (7) | 18 (6) | 35 (11) |
Hyperlipidemia | 445 (55) | 83 (41) | 170 (57) | 192 (61) | 394 (48) | 63 (31) | 145 (49) | 186 (59) |
Lipid-lowering medication use | 114 (14) | 1 (1) | 35 (12) | 78 (25) | 107 (13) | 4 (2) | 29 (10) | 74 (24) |
CHD at RA incidence/index | 89 (11) | 23 (11) | 35 (12) | 31 (10) | 90 (11) | 18 (9) | 36 (12) | 36 (11) |
RA disease characteristics | ||||||||
RF positivity at incidence/index | 537 (66) | 132 (65) | 198 (67) | 207 (66) | ||||
ExRA during the first yr | 32 (4) | 7 (4) | 12 (4) | 13 (4) | ||||
Highest ESR during the first yr of RA incidence, mm/h, mean (± SD) | 32.7 (25.7) | 38.9 (27.5) | 31.6 (25.1) | 29.9 (24.6) | ||||
Erosions/destructive changes during the first yr of RA incidence | 219 (27) | 51 (25) | 73 (25) | 95 (30) | ||||
Time from RA incidence date to first DMARD, mos, median (IQR) | 0.8 (0.0–5.3) | 4.5 (0.8–23.3) | 0.9 (0.1–5.3) | 0.5 (0.0–1.6) | ||||
Antirheumatic medication use during the first yr of RA incidence | ||||||||
Methotrexate | 261 (32) | 4 (2) | 83 (28) | 174 (55) | ||||
Hydroxychloroquine | 362 (44) | 50 (25) | 133 (45) | 179 (57) | ||||
Other DMARD | 127 (16) | 56 (28) | 44 (15) | 27 (9) | ||||
Biologics | 36 (4) | 0 (0) | 1 (0.3) | 35 (11) | ||||
Glucocorticoids | 445 (55) | 53 (26) | 177 (60) | 215 (68) | ||||
NSAID | 698 (86) | 159 (79) | 276 (93) | 263 (84) | 104 (13) | 11 (5) | 44 (15) | 49 (16) |
COX-2 inhibitors | 198 (24) | 0 (0) | 32 (11) | 166 (53) | 32 (4) | 1 (0.5) | 3 (1) | 28 (9) |
Antirheumatic medication use ever during followup | ||||||||
Methotrexate | 495 (61) | 86 (43) | 188 (64) | 221 (70) | ||||
Hydroxychloroquine | 496 (61) | 97 (48) | 188 (64) | 211 (67) | ||||
Other DMARD | 291 (36) | 104 (52) | 113 (38) | 74 (24) | ||||
Biologics | 175 (22) | 20 (10) | 68 (23) | 87 (28) | ||||
Glucocorticoids | 650 (80) | 137 (68) | 254 (86) | 259 (82) | ||||
NSAID | 738 (91) | 182 (90) | 273 (96) | 273 (87) | 196 (24) | 38 (19) | 91 (31) | 67 (21) |
COX-2 inhibitors | 393 (48) | 66 (33) | 158 (53) | 169 (54) | 94 (12) | 21 (10) | 40 (14) | 33 (10) |
RA: rheumatoid arthritis; BMI: body mass index; CV: cardiovascular; CHD: coronary heart disease; RF: rheumatoid factor; ExRA: extraarticular manifestations of RA; ESR: erythrocyte sedimentation rate; DMARD: disease-modifying antirheumatic drugs; IQR: interquartile range; NSAID: nonsteroidal antiinflammatory drugs; COX-2: cyclooxygenase.